• الرئيسية
  • الأخبار
  • حول
    • حول الكلية
    • كلمة العميد
    • مجلس الكلية
    • الهيكل التنظيمي
  • المعرض
  • المكتبة
  • النشاطات
    • النشاطات
    • المقالات
    • الجوائز
    • براءات الاختراع
    • الورش
    • المؤتمرات
    • الاعلانات
  • الأحداث القادمة
  • الكادر
  • البرنامج الأكاديمي
  • مشاريع التخرج
  • المحاضرات
  • الخدمات الإلكترونية
  • English
default image default image default image
default image
default image
default image

Advances in the Treatment of Parkinson’s Disease

08/12/2022
  مشاركة :          
  81

Parkinson's disease (PD) is the second most familial neurological disorder, after Alzheimer's disease, that mostly affects the mobility of old age people. Rigidity, tremor, akinesia, and postural instability are the most frequent symptoms, which are produced by the massive loss of dopaminergic neurons projecting from the Substantia nigra (SN) to the striatum (Dhanalakshmi, et al. 2016). PD is a complex, chronic, progressive, syndromal neurodegenerative illness that manifests clinically at the age of sixty. With 7-10 million Parkinsonians globally, PD is increasingly becoming a global community disease. By 2030, it is estimated that 8.7–9.3 million Parkinsonians would live in the world's top ten most populous countries. (Farombia, et al. 2019).<br />PD is a frequent cause of morbidity that affects 1–2 per 1000 people at any time, with the elderly being the most affected. Furthermore, men are somewhat more affected than women. There may be an increase in disease recurrence that cannot be explained just by population demographic changes. The clinical diagnosis accuracy is thought to increase as a result of the revised diagnostic criteria. Increased knowledge of PD genetic risk factors, together with data on environmental risk factors, will almost certainly lead to a superior understanding of the disease's origin in the near future. (Storstein, et al. 2017).<br />Linked to the etiopathogenesis of PD, oxidative stress and neuroinflammation have been the two central pathways in microglial cell activation that contribute to progressive neuronal degeneration and provide a promising therapeutic target in PD. The activation and release of proinflammatory cytokines include interleukin 1-β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor (TNF-α)<br />A balance between pro- and antioxidant systems is usually essential to maintain cellular homeostasis. As a result, one of the newest trends is the use of antioxidants to restore the cellular antioxidant system which acts as therapeutic strategies to protect vulnerable DA-ergic neurons from oxidative stress and inflammation that results. In therapeutics, anti-inflammatory drugs' side effects and synthetic antioxidants' pro-oxidant activity are of concern. This issue has changed the emphasis of medication development to plant extracts and plant-derived phytochemicals with antioxidant and anti-inflammatory properties for therapeutic and preventative advantages in PD. As a result, in recent years, pharmacological treatment has focused on the development of innovative nutraceutical-based plant-derived phytochemicals with strong antioxidant and anti-inflammatory capabilities and low cytotoxic effects. (Javed, et al. 2019).<br />Surprisingly, the World Health Organization (WHO) promotes the use of traditional medicinal herbs for treatment and prevention. However, no experimental investigation on the preventive potential of T. Officinale, for example, against rotenone-induced neurotoxicity in rats as an experimental model of PD has been published too far. T. Officinale (known as Dandelion) is chosen because it is a part of the Compositae family (Asteracea), a perennial herb that is typically viewed as a weed that can be found almost anywhere. It has antioxidant properties, as well as radical scavengers, enzyme inhibitors, metal chelators, hydrogen donors, and singlet oxygen quenchers. T. Officinale possesses strong radical scavenging activity and antioxidant capacity due to its greater phenolic and flavonoid content. T. Officinale's antioxidant properties are transferred into tissue antioxidant status. (Aremu, et al. 2019).<br /><br />By: Dr. Khawla Adnan Baqir

جامعة المستقبل

مؤسسة تعليمية تابعة لوزارة التعليم العالي والبحث العلمي في العراق

روابط مهمة

وزارة التعليم العالي

اللجنة التوجيهية

المدراء

الأكاديميون

الكادر التدريسي

الطلبة

أنظمة الدراسات

عملية التقييم

الهيكل التنظيمي

القواعد واللوائح

معلومات الخريجين

المواقع البحثية

Scopus

Research Gate

Google Scholar

ORCID

Web Of Science

مركز المساعدة

حول الجامعة

الكليات والأقسام

البوبات الألكترونية

دليل الجامعة

تواصل معنا

جامعة المستقبل - جميع الحقوق محفوظة ©2025